XLO (STOCKS)
Xilio Therapeutics, Inc. Common Stock
$8.240000
-0.070000 (-0.84%)
Prev close: $8.310000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- René Russo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $55.40M
- Employees
- 73
- P/E (TTM)
- -2.28
- P/B (TTM)
- 0.66
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
2
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.58 | $-0.67 | +0.0866 | +12.99% |
|
Dec 2025 (Q4)
|
$0.81 | $-1.70 | +2.5068 | +147.74% |
|
Sep 2025 (Q3)
|
$-0.08 | $-0.42 | +0.3402 | +80.20% |
|
Jun 2025 (Q2)
|
$-2.24 | $-1.13 | -1.1088 | -98.02% |
Financial Statements
| Revenues | $53.48M |
| Benefits Costs and Expenses | $25.50M |
| Costs And Expenses | $68.95M |
| Nonoperating Income/Loss | $10.94M |
| Operating Expenses | $95.73M |
| Research and Development | $67.61M |
| Other Operating Expenses | $28.12M |
| Operating Income/Loss | -$42.24M |
| Income/Loss From Continuing Operations After Tax | -$31.30M |
| Income/Loss From Continuing Operations Before Tax | $27.98M |
| Net Income/Loss | -$31.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$31.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$31.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.61 |
| Diluted Earnings Per Share | -$4.61 |
| Basic Average Shares | 159,921,983 |
| Assets | $163.49M |
| Current Assets | $154.21M |
| Noncurrent Assets | $9.28M |
| Fixed Assets | $3.68M |
| Other Non-current Assets | $5.60M |
| Liabilities | $90.94M |
| Current Liabilities | $42.96M |
| Accounts Payable | $1.06M |
| Other Current Liabilities | $41.90M |
| Noncurrent Liabilities | $47.98M |
| Equity | $72.55M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $72.55M |
| Liabilities And Equity | $163.49M |
| Net Cash Flow From Operating Activities | -$56.31M |
| Net Cash Flow From Operating Activities, Continuing | -$56.31M |
| Net Cash Flow From Investing Activities | -$1.05M |
| Net Cash Flow From Investing Activities, Continuing | -$1.05M |
| Net Cash Flow From Financing Activities | $118.65M |
| Net Cash Flow From Financing Activities, Continuing | $118.65M |
| Net Cash Flow | $61.29M |
| Net Cash Flow, Continuing | $61.29M |
| Comprehensive Income/Loss | -$31.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$31.30M |
| Other Comprehensive Income/Loss | -$32.13M |